3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations

3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations

Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week.